Dr. Reddy's Laboratories Limited — Investor Meet, 28-07-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Dr. Reddy's Q1FY27 revenue hit ₹8,071 Cr, down 5.6% YoY, largely due to lower lenalidomide sales and a ₹240 Cr semaglutide API provision. EBITDA margin was 12.5%. Excluding these, management estimates ~18% and aims for ~20% in Q2. The base business (ex-lenalidomide) grew double-digits. Semaglutide supplies are targeted to resume by November, with high confidence in issue resolution and 6-7 million pens expected by March. Abatacept's USFDA inspection received 7 addressable observations, with December 2026 remaining the approval goal. India business organic growth was robust at 15.5%. The company maintains focus on strategic growth areas.